It has been found that unlike BACE1, GS has demonstrated to be a highly manageable target for AD, at least in terms of the development of orally bioavailable GS inhibitors (GSIs) with brain-penetrating capacity [66]. The gene discussed is BACE1; the disease is Alzheimer disease.